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Abstract
Objective: The aim of this retrospective study is to evaluate the 
safety and performance of the Perceval sutureless valve in patients 
undergoing aortic valve replacement. We report the 30-day clinical 
outcomes of 139 patients. 
Methods: From January 2014 to December 2016, 139 patients 
underwent sutureless aortic valve replacement. Their operation 
notes, National Adult Cardiac Surgery Database and perioperative 
transoesophageal echocardiography findings were studied retro-
spectively. 
Results: Ninety-two patients underwent isolated aortic valve 
replacement (group A) with Perceval valve and 47 patients had com-
bined procedures of aortic valve replacement and coronary artery 
bypass grafting (group B). The patients received a size S (n=23), M 
(n=39), L (n=42) or XL (n=35) prosthesis. Perceval valve was success-
fully implanted in 135 (97.1%) patients. Mean cross-clamping time 
and bypass time were 40 and 63 minutes for isolated cases, while 
68 and 107 minutes for combined cases. Three (2.1%) patients died 
within 30 days. Four patients suffered stroke and 5 patients went 
into acute renal failure. Median intensive care unit and hospital stay 
was 2 and 8.5, respectively. Four valves were explanted due to sig-
nificant paravalvular leak after surgery. Five patients had permanent 
pacemaker as a result of complete heart block and mean postopera-
tive drainage was 295 mL for isolated case and 457 mL for combined 
cases. The mean gradient across Perceval valve was 12.5 mmHg 
while its effective orifice area was 1.5 cm2. 
Conclusion: Early postoperative results showed that Perceval 
valve is safe. Further follow up is needed to evaluate the long-term 
outcome with this bioprosthesis.
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Abbreviations, acronyms & symbols
AVR
CABG
CPB
EuroSCORE
FEV1
ICU
NACSA
NICOR
PVL
SCTS
STS
TAVI
TOE
 = Aortic valve replacement 
 = Coronary artery bypass grafting
 = Cardiopulmonary bypass 
 = European System for Cardiac Operative Risk Evaluation 
 = Forced expiratory volume in 1 second 
 = Intensive care unit
 = National Adult Cardiac Surgery Audit 
 = National Institute for Cardiovascular Outcomes Research 
 = Paravalvular leak
 = Society for Cardiothoracic Surgeons 
 = Society of Thoracic Surgeons 
 = Transfemoral aortic valve implantation
 = Transesophageal echocardiography
INTRODUCTION
Severe aortic valve stenosis is a common cardiac disease 
among the elderly. Due to the increasing age of the patient 
population in the Western world, there has been an increase in the 
prevalence of patients with valvular heart disease eligible for aortic 
valve replacement (AVR)[1]. AVR is the treatment of choice for aortic 
valve stenosis when it is severe aortic stenosis (≤ 1 cm2/m2) and 
symptomatic, or asymptomatic with left ventricular dysfunction, 
or combined with other cardiac surgery procedure[2]. Given the 
increasing number of comorbidities and increasing patient age, a 
tendency has emerged to use biological valve implants, avoiding 
the need for long-term anticoagulation therapy.
Although transapical or transfemoral aortic valve 
implantations (TAVIs) have been introduced for high-risk patients 
ineligible for conventional AVR using cardiopulmonary bypass 
(CPB), it has its own limitations, e.g., significantly increased 
costs, inability to remove the calcified aortic valve, and the high 
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The heart is vented through the right superior pulmonary 
vein. Antegrade cardioplegia is the method of choice at our 
institution for myocardial protection. Continuous carbon dioxide 
insufflation was used routinely after sternotomy until closure of 
the aortotomy. The ascending aorta was incised transversally 1.5 
cm above the sinotubular junction in order to leave a free edge 
for closure of the aortotomy after implantation of the device. The 
aortic valve was removed, and the annulus was decalcified in the 
usual fashion. The aortic orifice was measured with the original 
sizer of the bioprosthesis.
Three 4-0 polypropylene guiding sutures were passed at the 
nadir of the aortic annulus. An appropriately sized prosthesis 
was collapsed in a side table and placed into the manufacturer’s 
holder. 
The three guiding sutures were passed through the three 
green holes arising from the annular ring of the prosthesis, which 
was consequently seated on the debrided annulus. Once the 
delivery system is in position, the stent is deployed by turning the 
release screw and leaving the valve in place. The delivery system 
and the guiding sutures are removed. The field was rinsed with 
warm saline, and the prosthesis was dilated at four atmospheres 
for 30 seconds. After closure of the aortotomy, transesophageal 
echocardiography (TOE) was performed to assess the correct 
implantation of the prosthesis and the presence of any PVL.
RESULTS
The mean age of the 139 patients was 74.3 years (range 
47-86 years); 21.6% of patients were ≥ 80 years old (Table 
1). The procedure success rate was 97.1%. In four (2.8%) 
patients Perceval valve was explanted mainly due to severe 
PVL, erroneous sizing or malpositioning discovered during 
perioperative echocardiography. In each one of these cases, a 
different prosthetic valve was eventually implanted. Mean cross-
clamping time and bypass time were 40 and 63 minutes for 
isolated cases while 68 and 107 minutes for combined cases.
Size S (annulus range 19-21 mm) was implanted in 23 (17%) 
of patients, size M (annulus range 21-23 mm) in 39 (28%), size 
L (annulus range 23-25 mm) in 42 (30%) and size XL (annulus 
range 25-27 mm), which was available since July 2012, was 
implanted in 35 (25%) of the eligible patients. 
The mean length of intensive care unit (ICU) stay was 3.4 
days (range 1-32 days, median 1 day) in isolated AVR while it was 
6.8 days (range 1-93 days, median 3 days) in combined cases. 
Hospital stay was 11.7 days (median 8, range 4-48) for isolated 
cases while it was 18.4 days (median 9, 4-225) for combined 
cases (Tables 2 and 3). 
No cases of unanticipated adverse device effects, valve 
thrombosis, secondary valve dislodgement or valve-related 
haemolytic anaemia were reported. Five (3.6%) patients 
developed renal failure and were connected to continuous 
venovenous hemofiltration leading to recovery of renal function. 
Forty-six (33%) patients had postoperative atrial fibrillation, were 
treated with betablockers or amiodarone and returned to sinus 
rhythm. A total of 4 (2.8%) postoperative strokes occurred and 3 
(2.1%) cases of early bleeding led to reoperation. The incidence 
rate of permanent pacemaker implantation was overall 3.6%.
incidence of paravalvular leak (PVL), pacemaker implantation 
and neurological events[3].
In last few years sutureless aortic valve bioprostheses 
have been developed to facilitate surgical AVR, reduce aortic 
cross-clamping and CPB time and curtail risk of mortality 
and morbidity. Sutureless aortic bioprosthesis implantation 
is a feasible alternative for high-risk patients with aortic valve 
disease[4]. The Perceval valve (Sorin Group, Saluggia, Italy) is 
a bioprosthetic heart valve made of bovine pericardium that 
allows a fast implantation through a sutureless technique. The 
current study reports our single-centre experiences regarding 
the early outcomes of Perceval valve implantation.
METHODS
The Perceval valve is a surgical bioprosthetic heart valve 
composed of glutaraldehyde-fixed bovine pericardium treated 
with homocysteic acid in order to remove the free aldehyde 
residues and prevent the calcification process. It is fixed in a metal 
cage made up of an alloy of nickel and titanium, known as nitinol. 
Currently, four sizes of the Perceval S aortic valve prosthesis are 
available: small — S (19-21 mm); medium — M (22-23 mm), large 
— L (24-25 mm) and extra-large XL (27 mm). Hence, Perceval S can 
be used for annulus sizes ranging from 19 to 27 mm.
We performed a retrospective analysis of a consecutive series 
of patients (n = 139) who underwent AVR with Perceval valve 
between January 2014 and December 2016. They were either 
isolated AVR (group A, n = 92) or combined with coronary artery 
bypass grafting (CABG, group B, n = 47). Inclusion criteria were 
severe aortic valve stenosis with indication of valve replacement, 
patients who agreed to participate in the clinical evaluation, 
patients wishing to have a tissue valve, no contraindication for 
Perceval valve, and signed informed consent. These patients 
were operated by six different surgeons. During the same period, 
312 patients had AVR with conventional Perimount Magna 
biological valve by four different surgeons.
Patients with ascending aortic aneurysm or dissection, 
emergency intervention, acute endocarditis, congenital bicuspid 
aortic valve (Seivers type 0) or aortic annulus greater than 27 
mm or less than 21 mm were excluded. The ratio between the 
diameter of the sinotubular junction and aortic annulus should 
not exceed 1.3 mm. Patients with known nickel hypersensitivity 
were also avoided.
The operative risk of these patients was estimated according 
to the logistic European System for Cardiac Operative Risk 
Evaluation (logistic EuroSCORE). In this study, we have used logistic 
EuroSCORE as we submit patient’s risk assessment as logistic 
EuroSCORE to National Adult Cardiac Surgery Audit (NACSA) 
database and it is easier to retrieve in this form. The data used in 
this analysis were extracted from NACSA. The audit is managed by 
National Institute for Cardiovascular Outcomes Research (NICOR), 
with clinical direction and strategy provided by the Society for 
Cardiothoracic Surgeons (SCTS) and the Project Board.
Surgical Technique
After a full median sternotomy, standard CPB was established 
by cannulation of the ascending aorta and the right atrium. 
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Table 1. Preoperative summary.
Total 
n = 139
n
%
Gender (Male/Female) 65/74 47/53
Procedure types
Isolated aortic valve replacement (group A) 92 66
AVR + CABG or other procedures (group B) 47 34
Cigarette smoking history 83 60
History of hypertension 106 76
Renal disease at time of surgery 1 0.7
History of pulmonary disease (e.g. COPD, asthma) 2 1.44
History of neurological disease (e.g. TIA, CVA) 25 18
Angina status pre-surgery
0. No angina 49 35
1. No limitation of physical activity 33 24
2. Slight limitation of ordinary activity 29 21
3. Marked limitation of ordinary physical activity 25 18
4. Symptoms at rest or minimal activity 3 2
Dyspnoea status pre-surgery
1. No limitation of physical activity 12 8.7
2. Slight limitation of ordinary physical activity 53 38
3. Marked limitation of ordinary physical activity 71 51
4. Symptoms at rest or minimal activity 3 2
History of Diabetes mellitus 30 22
Preoperative heart rhythm
0. Sinus rhythm 109 78
1. Atrial fibrillation/flutter 28 20
2. Complete heart block/pacing 2 1.4
Ejection fraction category
1. Good (LVEF > 50%) 111 80
2. Fair (LVEF 30-50%) 22 16
3. Poor (LVEF < 30%) 6 4
Range Mean Median
Age of patients at time of procedure                 47-86 74.3 75.5
Logistic EuroSCORE comparison                 0.53-18.886 3.26 2.457
Height (cm) 140-185 162 162
Weight (kg) 40.3-158 79 74
AVR=aortic valve replacement; CABG=coronary artery bypass grafting; COPD=chronic obstructive pulmonary disease; 
CVA=cerebrovascular accident; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection 
fraction; TIA=transient ischemic attack
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DISCUSSION
Magovern & Cromie[5] introduced the concept of sutureless 
aortic valve in the 1960s with the ball-cage-type mechanical 
valve for sutureless implantation. It had its own disadvantages, 
e.g. high incidence of PVLs, bulky size and not suitable for 
small annuli[6], high incidence of thromboembolism (42%) and 
reoperation (16%)[6]. This valve continued to be used until 1980.
When aortic valve is replaced surgically, sutures are placed into 
the annulus and then through the sewing cuff of the prosthetic 
valve. While at sutureless aortic valve, it obviates the need to put 
sutures to fix the valve, and thus make the procedure faster, cross-
clamp and CPB times shorter, both are independent predictors of 
30 day postoperative mortality after adult cardiac surgery[7]. 
High-risk patients, particularly those undergoing prolonged 
concomitant surgery and redo surgery, could benefit from 
reduced length of time of the implantation by avoiding the 
need to use sutures to secure the bioprosthesis within the aortic 
annulus. Shrestha et al.[8] also confirmed the safety and efficacy 
of the sutureless aortic valve in patients requiring concomitant 
procedures. This is important as, according to the Society of 
Table 2. Postoperative summary. 
Group A 
n = 92
Group B 
n = 47
Range Mean Median Range Mean Median
Cumulative cross-clamp time (min)                  21-114 40 37 28-127 68 61
Cumulative bypass time                                   25-172 63 59 38-403 107 87
Postoperative blood loss at 12 hours                        50-2000 295 225 50-1200 457 400
ICU stay in days                                                 1   32 3.4 1 1   93 6.8 3
Reoperation for bleeding, tamponade or valvular problems 2 (1.4%) 1 (0.7%)
ICU=intensive care unit
Table 3. Postoperative summary. 
n = 139 %
Reoperation for bleeding, tamponade or valvular problems 3 2.1%
Sternal wound infection 2/139 1.43%
New postoperative neurological dysfunction 4/139 2.8%
New HF/dialysis postoperatively 5/139 3.6%
Patient status at discharge (mortality) 3/139 2.1%
SIRS 21/139 15%
Arrhythmias
None 88 63%
AF/flutter 46 33%
Permanent pacemaker 5 3.6%
AF=atrial fibrillation; HF=hemofiltration; SIRS=systemic inflammatory response syndrome
The mean gradient across Perceval valve was found to be 
higher for the smaller and lower for the larger valves. It ranges 
from 6-18 mmHg and its mean value was 12.5 mmHg. Similarly, 
its effective orifice area varies according to the valve sizes but its 
mean value was 1.5 cm2.
In-hospital mortality was 2.1% (n=3). The first patient was a 
70 years old man who had AVR and CABG. He was re-intubated 
for respiratory compromise on day 3 and aspirated during the 
procedure. He went into sepsis, renal failure and developed 
ischemic colon. Finally, he died on day 13. The next one was a 
70 years old male, chronic smoker, severe chronic obstructive 
pulmonary disease, forced expiratory volume in 1 second (FEV1) 
1.4 lit (53% predicted). He underwent uneventful surgery and ICU 
stay. On day 4, he had a run of ventricular tachycardia, followed 
by respiratory and cardiac arrest. He was intubated, resuscitated 
and chest was opened. There was no evidence of tamponade, 
at this stage he went into ventricular fibrillation and finally died 
despite all resuscitation attempts. The last one was a 70 years 
old, 47 kg frail woman with severely impaired left ventricle and 
severe aortic stenosis. She had uneventful surgery but died of 
low output syndrome and heart failure on day 14.
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The PARTNER trial showed a significantly higher incidence 
of PVL following TAVI than after surgical AVR at both 1 and 2 
years[11]. PVL has been identified as an independent predictor 
of late mortality after TAVI[12]. D’Onofrio et al.[13] showed that the 
incidence of PVL (at least mild) was higher in a transapical TAVI 
group compared with a sutureless bioprosthesis group (44.7% vs. 
15.8%, respectively, P=0.001). Unlike TAVI, it is technically possible 
to perform repositioning and to exchange the sutureless valve 
intraoperatively if the result is unsatisfactory.
PVL can be the result of inadequate sizing, malpositioning or 
inappropriate decalcification of the annulus[14]. Recent evidence 
from TAVI trials has demonstrated a significant correlation 
between PVL and poorer outcomes. PVL was demonstrated 
to be a significant predictor of one-year mortality, even after 
multivariable adjustment. 
Thoracic Surgeons (STS) database, the proportion of candidates 
requiring concomitant CABG has risen from 5 to 25% over the 
past 20 years.
The effective orifice area of the valve is more for any given 
valve size as there is no ring for valve anchorage. This would be 
particularly beneficial for patients with small aortic roots where 
risk of patient prosthesis mismatch is high[9]. 
Sutureless valves are also advantageous in minimally invasive 
AVR as it is technically difficult to put annular sutures in such 
cases because of the limitation of working space. Sutureless 
valves obviate this technical difficulty.
The durability of the Perceval valve is also an issue. Englberger 
et al.[10] presented the longest follow-up study for a sutureless 
bioprosthesis (5-year follow-up) and suggested that sutureless valves 
become an option for all patients with indicated biological AVR.
Table 4. Comparison of our results with other published series using sutureless valves.
Study
Type of 
valve
Mean 
logistic 
EuroSCORE
Cross-clamp 
time min 
Isolated AVR
Bypass time 
min
 Isolated AVR
Severe PV 
leak/replaced
valve N (%)
AV block
N (%)
Mortality
Mean
gradient 
mmHg
Mean effective 
orifice area 
cm2
Our study 
(2018) n=139
Perceval S
3.26 (0.53-
18.8)
40 (21-114) 63 (25-172) 4 (2.8%) 5 (3.6%) 3 (2.1%) 12.5 (6-18) 1.5
D’Onofrio[13]  
(2012) n=51
Perceval S 14.2±8.1 44±17 69±26 2 (5.3%) 0 10.9±3.72
Folliguet[14]  
(2012) n=208
Perceval S 8.7±5.3 30.1±12.2 50.3±22.8 9 (4.3%) 16 (7.7%) 5 (2.4%) 10.4±4.3 1.4±0.4
Kocher[20] 
(2013) n=146
Edwards 
Intuity
7.9±6.5 41.1±10.6 66.3±18.7
2 (1.9%) but 
after 30 days
10 (7.1%) 3 (2.1) 8.8±3.0 1.7±0.2
Martens[21] 
(2011) n=140
ATS 3f Enable
58.1±25.1
Including 
combined 
procedures
84.9±34.2
Including 
combined 
procedures
3 (2.1%) 5 (3.6%) 10.24±4.2 1.75±0.45
Santarpino[22]  
(2012) n=83
Perceval S 10±7.5 36±12.7 66±21 1 (1.2%) 3 (3.6%) 2 (2.4%) 13.4±2.8
Flameng[18] 
(2011) n=32
Perceval S 9.99 17 (12-34) 46(24-120)
1 (3.1%) 
6-12 
months 
after 
surgery
3 (9.4%) 
6-12 
months 
after 
surgery
1.5 (0.8-2.2)
Shrestha[8] 
(2014) n=243
Perceval S 12.1
50.7±22.8 
including 
combined 
procedures
78.9±32.3
 including 
combined 
procedures
4 (1.6%) 14 (5.9%) 5(2.1%) 10.1 ± 4.7 1.5 ± 0.4
Cavalier trial[19] 
(2016) n = 658
Perceval S 10.2±7.8 35.3±12.1 58.4±20.2 5 (0.8) 42 (6.7%) 23 (3.7) 10.24 1.46
Gilmanov[23] 
(2014) n=133
Predominantly 
Perceval S
7.5  (4.8-11) 56 (48-72.5) 90 (78-108.5) 3 (2.3%) 2 (1.5) 12
Pollari[16] 
(2014) n=133
Perceval S 14±7.4 35±12 71±11 0 5 (6.1%)
Dalén[24]
(2016) n=182
Perceval S 10.6±7.5 41±17 69±23 3 (1.6)
AV = atrioventricular; AVR=aortic valve replacement;  EuroSCORE=European System for Cardiac Operative Risk Evaluation;
PV = paravalvular.
13
Brazilian Journal of Cardiovascular Surgery 
Braz J Cardiovasc Surg 2018;33(1):8-14Mujtaba SS, et al. - Perceval valve: Freeman experience
Unlike TAVI and similarly to conventional AVR, the sutureless 
AVR approach involves excision of the calcified valve and 
prosthesis placement under direct visualization on a still heart, 
which may reduce the risk of misplacement and PVL[15]. Pollari et 
al.[16] found shorter ICU stays, hospital stays, and intubation times 
in the sutureless group then in the stented group.
Even in cases requiring explantation of Perceval, the 
procedure was easy and the Perceval valve was removed 
without technical issues, as previously described[17]. Careful 
patient selection and echocardiographic assessment are crucial 
in choosing the proper size. Correct sizing of the valve is critical 
to minimize PVL and this should be performed with TOE and 
intraoperative sizing.
We have compared our perioperative and early postoperative 
results with other published series using sutureless valves (Table 
4). Most of the authors have used Perceval valve except two 
who used Edwards Intuity and ATS 3f Enable valves. Our mean 
logistic EuroSCORE is less then all of the studies as we have least 
comorbidities. Our cross-clamp and bypass time for the isolated 
Perceval AVR is almost the same as for most of the studies but 
longer then Folliguet et al.[14], Flameng et al.[18], Cavalier trial[19] and 
Pollari et al.[16]. We replaced 2.8% valves for severe PVL. This rate 
was 1.9%, 2.1%, 1.2%, 1.6% and 0.8% for Kocher et al.[20], Martens 
et al.[21], Santarpino et al.[22], Shrestha et al.[8] and Cavalier trial[19], 
respectively. Folliguet et al.[14] explanted 4.6% valves for severe PVL. 
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